Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-FAST: Zoledronic Acid in HR+ Breast Cancer
NCT00050011Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2002
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Novartis. Primary endpoint: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) at 12 months. Started Sep 2002; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00050011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050011.